Attending to modifiable risk factors is an important treatment target in patients with atrial fibrillation treated with anticoagulants to reduce thromboembolic and bleeding events.
The USPSTF concluded that the current evidence is insufficient to assess the balance of benefits and harms of screening for elevated blood lead levels in asymptomatic children and pregnant women.
The use of plasma infusion therapies (often called “vampire” treatments, in which people undergo infusions of a young donor’s blood) is on the rise across the United States, often costing thousands of dollars per treatment.
Questions about the generalizability of previous data on dual antiplatelet therapy after minor ischemic stroke or high-risk transient ischemic attack lead investigators of the POINT trial to conduct a similar study in an international population.
Children born with sickle cell disease in low-resource regions of the world often remain undiagnosed and therefore do not receive appropriate treatment.
The US Preventive Services Task Force (USPSTF) has concluded that current evidence is insufficient for assessing the balance of harms and benefits of screening for elevated blood lead levels in asymptomatic children and pregnant women.
